Compare Cassava Sciences Inc (FLNA) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs JPMorgan Ultra Short Income ETF — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JPST | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $50.78 |
52-Week Low | $0.87 | $50.40 |
Enterprise Value | -$34.93M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% with a bearish technical signal. The ETF focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends. Recent institutional buying includes Financial Management Professionals increasing its stake by 4.7% in Q2 2026 (SEC filing, August 11, 2026).
Outlook remains stable for risk-averse investors seeking yield with low volatility. Key risks include interest rate hikes and inflation pressures, as noted in Fed commentary (Zacks Investment Research, July 31, 2026). The ETF's short duration mitigates rate sensitivity, but macroeconomic shifts could impact returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
